{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["antihypertensive agents", "genetic polymorphisms", "nicotinamide phosphoribosyltransferase", "nitric oxide", "pharmacogenetics", "preeclampsia", "sFlt-1", "visfatin/NAMPT"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "33944612", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "01"}, "DateRevised": {"Year": "2022", "Month": "10", "Day": "17"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "05", "Day": "04"}], "ELocationID": ["10.2217/pgs-2021-0006"], "Journal": {"ISSN": "1744-8042", "JournalIssue": {"Volume": "22", "Issue": "8", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "Pharmacogenomics", "ISOAbbreviation": "Pharmacogenomics"}, "ArticleTitle": "<i>NAMPT</i> single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide\u00a0formation, sFlt-1 and antihypertensive therapy response in preeclampsia.", "Pagination": {"StartPage": "451", "EndPage": "464", "MedlinePgn": "451-464"}, "Abstract": {"AbstractText": ["<b>Aim:</b> We examined the relationships between visfatin/NAMPT and nitrite concentrations (a marker of nitric oxide [NO] formation) or sFlt-1 levels in 205 patients with preeclampsia (PE) responsive or nonresponsive to antihypertensive therapy, and whether <i>NAMPT</i> SNPs rs1319501 and rs3801266 affect nitrite concentrations in PE and 206 healthy pregnant women. <b>Patients & methods:</b> Circulating visfatin/NAMPT and sFlt-1 levels were measured by ELISA, and nitrite concentrations by using an ozone-based chemiluminescence assay. <b>Results:</b> In nonresponsive PE patients, visfatin/NAMPT levels were inversely related to nitrite concentrations and positively related to sFlt-1 levels. <i>NAMPT</i> SNP rs1319501 affected nitrite concentrations in nonresponsive PE patients and was tightly linked with <i>NAMPT</i> functional SNPs in Europeans. <b>Conclusion:</b><i>NAMPT</i> SNP rs1319501 and visfatin/NAMPT affect NO formation, sFlt-1 levels and antihypertensive therapy response in PE."]}, "AuthorList": [{"Identifier": ["0000-0001-5491-6709"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Graduate Program in Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil."}], "LastName": "Pereira", "ForeName": "Daniela A", "Initials": "DA"}, {"Identifier": ["0000-0002-6168-7470"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biophysics & Pharmacology, Institute of Biosciences, Universidade Estadual Paulista (UNESP), Botucatu, S\u00e3o Paulo, Brazil."}], "LastName": "Sandrim", "ForeName": "Valeria C", "Initials": "VC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Surgery, University of Mississippi Medical Center, Jackson, MS\u00a0392164, USA."}], "LastName": "Palei", "ForeName": "Ana C", "Initials": "AC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS\u00a0392164, USA."}], "LastName": "Amaral", "ForeName": "Lorena M", "Initials": "LM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Graduate Program in Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil."}], "LastName": "Belo", "ForeName": "Vanessa A", "Initials": "VA"}, {"Identifier": ["0000-0002-3738-2036"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatric Nursing & Human Sciences, Ribeirao Preto College of Nursing, University of Sao Paulo, Ribeirao Preto, S\u00e3o Paulo, Brazil."}], "LastName": "Lacchini", "ForeName": "Riccardo", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology & Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, S\u00e3o Paulo, Brazil."}], "LastName": "Cavalli", "ForeName": "Ricardo C", "Initials": "RC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, S\u00e3o Paulo, Brazil."}], "LastName": "Tanus-Santos", "ForeName": "Jose E", "Initials": "JE"}, {"Identifier": ["0000-0002-8331-3525"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Graduate Program in Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil."}, {"Identifier": [], "Affiliation": "Department of Genetics, Ecology & Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil."}], "LastName": "Luizon", "ForeName": "Marcelo R", "Initials": "MR"}], "GrantList": [{"GrantID": "P20 GM121334", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}, {"GrantID": "U54 GM115428", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Pharmacogenomics", "NlmUniqueID": "100897350", "ISSNLinking": "1462-2416"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antihypertensive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "31C4KY9ESH", "NameOfSubstance": "Nitric Oxide"}, {"RegistryNumber": "EC 2.4.2.12", "NameOfSubstance": "Nicotinamide Phosphoribosyltransferase"}, {"RegistryNumber": "EC 2.4.2.12", "NameOfSubstance": "nicotinamide phosphoribosyltransferase, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "FLT1 protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-1"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antihypertensive Agents"}, {"QualifierName": ["genetics"], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["genetics"], "DescriptorName": "Nicotinamide Phosphoribosyltransferase"}, {"QualifierName": ["genetics"], "DescriptorName": "Nitric Oxide"}, {"QualifierName": ["genetics"], "DescriptorName": "Polymorphism, Single Nucleotide"}, {"QualifierName": ["genetics"], "DescriptorName": "Pre-Eclampsia"}, {"QualifierName": [], "DescriptorName": "Pregnancy"}, {"QualifierName": ["genetics"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-1"}, {"QualifierName": [], "DescriptorName": "Young Adult"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat. Rev. Nephrol. 15(5), 275\u2013289 (2019).", "ArticleIdList": ["PMC6472952", "30792480"]}, {"Citation": "Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol. (Oxf.) 208(3), 224\u2013233 (2013).", "ArticleIdList": ["PMC3687012", "23590594"]}, {"Citation": "Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 62(4), 666\u2013673 (2013).", "ArticleIdList": ["PMC3856636", "23897068"]}, {"Citation": "Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123(24), 2856\u20132869 (2011).", "ArticleIdList": ["PMC3148781", "21690502"]}, {"Citation": "Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Ann. Clin. Lab. Sci. 32(3), 257\u2013263 (2002).", "ArticleIdList": ["12175088"]}, {"Citation": "Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 52(2), 402\u2013407 (2008).", "ArticleIdList": ["18574068"]}, {"Citation": "Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am. J. Obstet. Gynecol. 171(4), 944\u2013948 (1994).", "ArticleIdList": ["7943106"]}, {"Citation": "Pavlova T, Novak J, Bienertova-Vasku J. The role of visfatin (PBEF/Nampt) in pregnancy complications. J. Reprod. Immunol. 112, 102\u2013110 (2015).", "ArticleIdList": ["26451650"]}, {"Citation": "Porter B, Babbar S, Ye SQ, Maulik D. The role of nicotinamide phosphoribosyltransferase in pregnancy: a review. Am. J. Perinatol. 33, 1327\u20131336 (2016).", "ArticleIdList": ["27135957"]}, {"Citation": "Lovren F, Pan Y, Shukla PC et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 296(6), E1440\u2013E1449 (2009).", "ArticleIdList": ["19351806"]}, {"Citation": "Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem. Biophys. Res. Commun. 383, 503\u2013508 (2009).", "ArticleIdList": ["19393628"]}, {"Citation": "Vallejo S, Romacho T, Angulo J et al. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS ONE 6, 1\u20138 (2011).", "ArticleIdList": ["PMC3207864", "22073309"]}, {"Citation": "Romacho T, Valencia I, Ramos-Gonzalez M et al. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for toll-like receptor 4 and NLRP3 inflammasome. Sci. Rep. 10(1), 5386 (2020).", "ArticleIdList": ["PMC7096459", "32214150"]}, {"Citation": "Pereira DA, Sandrim VC, Palei ACT et al. NAMPT levels are inversely related to nitric oxide formation and positively related to soluble fms-like tyrosine kinase-1 levels in preeclampsia. Pregnancy Hypertens. 18, 137\u2013140 (2019).", "ArticleIdList": ["31610400"]}, {"Citation": "George EM, Granger JP. Mechanisms and potential therapies for preeclampsia. Curr. Hypertens. Rep. 13(4), 269\u2013275 (2011).", "ArticleIdList": ["PMC3788669", "21465139"]}, {"Citation": "Peir\u00f3 C, Romacho T, Carraro R, S\u00e1nchez-Ferrer CF. Visfatin/PBEF/Nampt: a new cardiovascular target? Front Pharmacol. 1(135), (2010).", "ArticleIdList": ["PMC3153009", "21833174"]}, {"Citation": "Romacho T, S\u00e1nchez-Ferrer CF, Peir\u00f3 C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013, 946427 (2013).", "ArticleIdList": ["PMC3697395", "23843684"]}, {"Citation": "Luizon MR, Belo VA, Palei AC et al. Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy. Hypertens. Res. 38(5), 361\u2013366 (2015).", "ArticleIdList": ["25716650"]}, {"Citation": "Luizon MR, Palei ACT, Belo VA et al. Gene\u2013gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 17(5), 427\u2013434 (2017).", "ArticleIdList": ["27168100"]}, {"Citation": "American College of Obstetricians and Gynecologists TFOHIP. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 122(5), 1122\u20131131 (2013).", "ArticleIdList": ["24150027"]}, {"Citation": "Luizon MR, Palei AC, Sandrim VC et al. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 14(6), 535\u2013541 (2014).", "ArticleIdList": ["24913092"]}, {"Citation": "Palei AC, Sandrim VC, Amaral LM et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 12(6), 489\u2013498 (2012).", "ArticleIdList": ["21769110"]}, {"Citation": "Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J. 10(1), 40\u201345 (2010).", "ArticleIdList": ["19704415"]}, {"Citation": "Encode. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57\u201374 (2012).", "ArticleIdList": ["PMC3439153", "22955616"]}, {"Citation": "Creyghton MP, Cheng AW, Welstead GG et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107(50), 21931\u201321936 (2010).", "ArticleIdList": ["PMC3003124", "21106759"]}, {"Citation": "Rosenbloom KR, Dreszer TR, Long JC et al. ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res. 40(Database issue), D912\u2013D917 (2012).", "ArticleIdList": ["PMC3245183", "22075998"]}, {"Citation": "Fishilevich S, Nudel R, Rappaport N et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford) 2017, bax028 (2017).", "ArticleIdList": ["PMC5467550", "28605766"]}, {"Citation": "Linhares ND, Pereira DA, Conceicao IM et al. Noncoding SNPs associated with increased GDF15 levels located in a metformin-activated enhancer region upstream of GDF15. Pharmacogenomics 21(8), 509\u2013520 (2020).", "ArticleIdList": ["32427048"]}, {"Citation": "Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263\u2013265 (2005).", "ArticleIdList": ["15297300"]}, {"Citation": "Goulopoulou S, Davidge ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol. Med. 21(2), 88\u201397 (2015).", "ArticleIdList": ["25541377"]}, {"Citation": "Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev. Mol. Med. 8(3), 1\u201320 (2006).", "ArticleIdList": ["16438753"]}, {"Citation": "Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation 21(1), 4\u201314 (2014).", "ArticleIdList": ["23890192"]}, {"Citation": "Kao CK, Morton JS, Quon AL, Reyes LM, Lopez-Jaramillo P, Davidge ST. Mechanism of vascular dysfunction due to circulating factors in women with pre-eclampsia. Clin. Sci. (Lond.) 130(7), 539\u2013549 (2016).", "ArticleIdList": ["26733722"]}, {"Citation": "Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649\u2013658 (2003).", "ArticleIdList": ["PMC151901", "12618519"]}, {"Citation": "Jiang Z, Zou Y, Ge Z, Zuo Q, Huang SY, Sun L. A role of sFlt-1 in oxidative stress and apoptosis in human and mouse pre-eclamptic trophoblasts. Biol. Reprod. 93(3), 73 (2015).", "ArticleIdList": ["26203176"]}, {"Citation": "Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc. Res. 115(5), 904\u2013914 (2019).", "ArticleIdList": ["30726882"]}, {"Citation": "Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 10, CD002252 (2018).", "ArticleIdList": ["PMC6517078", "30277556"]}, {"Citation": "Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 51(4), 960\u2013969 (2008).", "ArticleIdList": ["18259046"]}, {"Citation": "Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J. Pharmacol. Exp. Ther. 292, 606\u2013609 (2000).", "ArticleIdList": ["10640297"]}, {"Citation": "Taddei S, Virdis A, Ghiadoni L et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 37, 943\u2013948 (2001).", "ArticleIdList": ["11244022"]}, {"Citation": "L\u00f3pez-Jaramillo P, Narv\u00e1ez M, Calle A et al. Cyclic guanosine 3\u20323\u2032 monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br. J. Obstet. Gynaecol. 103, 33\u201338 (1996).", "ArticleIdList": ["8608095"]}, {"Citation": "Luizon MR, Palei AC, Cavalli RC, Sandrim VC. Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives. Pharmacogenomics 18(6), 571\u2013583 (2017).", "ArticleIdList": ["28358601"]}, {"Citation": "Luizon MR, Sandrim VC. Pharmacogenomic approaches that may guide preeclampsia therapy. Pharmacogenomics 14(6), 591\u2013593 (2013).", "ArticleIdList": ["23570460"]}, {"Citation": "Williams PJ, Morgan L. The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. Pharmgenomics. Pers. Med. 5, 37\u201351 (2012).", "ArticleIdList": ["PMC3513227", "23226061"]}, {"Citation": "Metzger IF, Luizon MR, Lacchini R, Ishizawa MH, Tanus-Santos JE. Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects. Nitric Oxide 28, 33\u201338 (2013).", "ArticleIdList": ["23069892"]}, {"Citation": "Muniz L, Luizon MR, Palei AC et al. eNOS tag SNP haplotypes in hypertensive disorders of pregnancy. DNA Cell Biol. 31(12), 1665\u20131670 (2012).", "ArticleIdList": ["23062210"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Luizon MR et al. Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension. Nitric Oxide 55\u201356, 62\u201369 (2016).", "ArticleIdList": ["27060232"]}, {"Citation": "Silva PS, Fontana V, Luizon MR et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur. J. Clin. Pharmacol. 69(2), 167\u2013177 (2013).", "ArticleIdList": ["22706620"]}, {"Citation": "Amaral LM, Pinheiro LC, Guimaraes DA et al. Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. J. Cell. Mol. Med. 17(10), 1300\u20131307 (2013).", "ArticleIdList": ["PMC4159028", "23890248"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Tanus-Santos JE. Inducible nitric oxide synthase as a possible target in hypertension. Curr. Drug Targets 15(2), 164\u2013174 (2014).", "ArticleIdList": ["24102471"]}, {"Citation": "Luizon MR, Pereira DA, Sandrim VC. Pharmacogenomics of hypertension and preeclampsia: focus on gene\u2013gene interactions. Front. Pharmacol. 9, 168 (2018).", "ArticleIdList": ["PMC5835759", "29541029"]}, {"Citation": "Luizon MR, Pereira DA, Tanus-Santos JE. Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions. Pharmacogenomics 19(18), 1423\u20131435 (2018).", "ArticleIdList": ["30398085"]}, {"Citation": "Bailey SD, Loredo-Osti JC, Lepage P et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55(10), 2896\u20132902 (2006).", "ArticleIdList": ["17003359"]}, {"Citation": "Bottcher Y, Teupser D, Enigk B et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab. 91(7), 2725\u20132731 (2006).", "ArticleIdList": ["16636125"]}, {"Citation": "Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 26(2), 107\u2013117 (2001).", "ArticleIdList": ["11241162"]}, {"Citation": "Adyshev DM, Elangovan VR, Moldobaeva N, Mapes B, Sun X, Garcia JG. Mechanical stress induces pre-B-cell colony-enhancing factor/NAMPT expression via epigenetic regulation by miR-374a and miR-568 in human lung endothelium. Am. J. Respir. Cell Mol. Biol. 50(2), 409\u2013418 (2014).", "ArticleIdList": ["PMC3930953", "24053186"]}, {"Citation": "Boyle AP, Hong EL, Hariharan M et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22(9), 1790\u20131797 (2012).", "ArticleIdList": ["PMC3431494", "22955989"]}, {"Citation": "Sun X, Elangovan VR, Mapes B et al. The NAMPT promoter is regulated by mechanical stress, signal transducer and activator of transcription 5, and acute respiratory distress syndrome-associated genetic variants. Am. J. Respir. Cell Mol. Biol. 51(5), 660\u2013667 (2014).", "ArticleIdList": ["PMC4224084", "24821571"]}, {"Citation": "Ooi DS, Ong SG, Heng CK, Loke KY, Lee YS. In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children. BMC Genomics 17(1), 974 (2016).", "ArticleIdList": ["PMC5124300", "27887573"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "5", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "4", "Hour": "12", "Minute": "18"}, {"Year": "2022", "Month": "6", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33944612", "PMC9552901", "10.2217/pgs-2021-0006"]}}], "PubmedBookArticle": []}